Latest News
Graviton BioScience's Investigational New Drug (IND) application for GV101 cleared for Friedreich's ataxia treatment
12 August 2026 - Graviton BioScience Corporation, a privately held, clinical-stage biotechnology company developing a diverse pipeline of therapeutics, including selective ROCK2 inhibitors for metabolic, inflammatory, fibrotic, and central nervous sy...
Galvanize Therapeutics' new Aliya EX System completes first commercial procedures
12 August 2026 - Galvanize Therapeutics Inc, a commercial-stage medical technology company focused on pulsed electric field (PEF) therapies for oncology and chronic lung disease, announced on Tuesday the completion of the first commercial procedures ...
Laekna's New Drug Application for LAE002 (afuresertib) accepted by China's NMPA
12 August 2026 - Chinese biotechnology company Laekna (HK:2105) announced on Tuesday that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Admi...
EIT Pharma's lonafarnib New Drug Application accepted for review by US FDA for chronic hepatitis D treatment
12 August 2026 - Biotechnology company EIT Pharma Inc announced on Tuesday that the US Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for lonafarnib for the treatment of chronic hepatitis D.Lonafarnib is an ...
AcuCort publishes Phase IV study results on patient use of Zeqmelit oral film
11 August 2026 - Swedish pharmaceutical company AcuCort AB (Spotlight Stock Market: ACUC), developer of the rapidly dissolving dexamethasone oral film Zeqmelit, on Tuesday announced that it has published results from its Phase IV study in the Journal...